HU-308 - a synthetic cannabinoid (CB2 agonist) studies completed

HU-308 - a synthetic cannabinoid (CB2 agonist) studies completed

Overview

HU-308 is a synthetic cannabinoid drug that acts as a cannabinoid agonist. It is highly selective for the CB2 receptor subtype, with a selectivity of over 5000x for CB2 vs CB1.

The abbreviation "HU" stands for Hebrew University.

Science and Research

2012 - Study ~ Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effects.

2011 - Study ~ Gadolinium-HU-308-incorporated micelles.

2011 - Study ~ CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling

2011 - Study ~ Cannabinoid-2 Receptor Activation Protects against Infarct and Ischemia/Reperfusion Heart Injury.

2008 - Study ~ Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor

2007 - Study ~ Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis

2007 - Interview ~ Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál Pacher

2006 - Study ~ Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation

2006 - News - Activation of CB2 receptor attenuates bone loss in osteoporosis

2005 - Study - Peripheral cannabinoid receptor, CB2, regulates bone mass

2005 - Study ~ Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation

2005 - Study ~ Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.

1999 - Study ~ HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.